I guess it's a "Boring Hold"... "Highlights  Cash at the end of...

I guess it's a "Boring Hold"...
"Highlights
 Cash at the end of September was $1.633 million
 Net operating cash outflows for the quarter totalled ($0.469 million).
 During the quarter, the Company
o Raised $1.3 million of gross proceeds through a placement to sophisticated investors to
accelerate its commercial activities.
o Generated further EmbryoCellectTM kit sales and services revenue in the September quarter.
Cash receipts from clients totalled $75,000 in the quarter.
o Signed its 8th exclusive distribution agreement, with Medicare International Trading Limited for
the sale of EmbryoCellect™ in China, Hong Kong and Macau.
o Completed the first EmbryoCellectTM training course held at RHS’ Adelaide facilities in August
2015. The course was attended by fifteen representatives from eleven clinics located in
Australia, China, Indonesia, Russia and Turkey. The course was designed to provide attendees
with detailed information on the EmbryoCellectTM protocols, an open discussion on PGS and
trends and observations relating to its clinical use, as well as hands-on practical experience
using the kit under the guidance of RHS staff.
o The CEO presented as an invited speaker at the Fertility Society of Australia meeting in
Canberra on 14-16 September on the topic of “Are we making PGS too complicated?”
 Subsequent to 30th September 2015, the Company
o Is scheduling a second client training course for November, based on positive feedback from
the client training held in August and further enquiries.
o Exhibited at the American Society for Reproductive Medicine meeting held in Baltimore on the
19-22nd October attended by both the CSO & CEO. The conference was attended by over 9,000
delegates from 83 countries and RHS was one of 201 exhibitors.
o Continues to progress PGS service discussions with Australian IVF providers
o Received a R&D tax offset of $221k
o Lodged an Export Market Development Grant application